Evidence map›Paper›PMID 39553226›Full record

ArticleAmerican journal of cancer research2024

A patient-derived xenograft mouse platform from epithelioid glioblastoma provides possible druggable screening and translational study.

Chiao-Yun Lin, Chen-Yang Huang, Cheng-Chi Lee, Lien-Min Li, Ya-Fang Lee, Shi-Ming Jung, Hsien-Chi Fan, An-Chi Lin, Cheng-Lung Hsu, Yin-Cheng Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chiao-Yun LinGynecologic Cancer Research Center, Chang Gung Memorial Hospital Linkou, Taoyuan 33305, Taiwan.
Chen-Yang HuangDepartment of Medicine, Chang Gung University Taoyuan 33305, Taiwan.
Cheng-Chi LeeDivision of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Chang Gung University Taoyuan 33305, Taiwan.
Lien-Min LiDepartment of Neurosurgery, Chang Gung Memorial Hospital, Linkou, Chang Gung University Taoyuan 33305, Taiwan.
Ya-Fang LeeDepartment of Neurosurgery, Chang Gung Memorial Hospital, Linkou, Chang Gung University Taoyuan 33305, Taiwan.
Shi-Ming JungDepartment of Medicine, Chang Gung University Taoyuan 33305, Taiwan.
Hsien-Chi FanDivision of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Chang Gung University Taoyuan 33305, Taiwan.
An-Chi LinGynecologic Cancer Research Center, Chang Gung Memorial Hospital Linkou, Taoyuan 33305, Taiwan.
Cheng-Lung HsuDepartment of Medicine, Chang Gung University Taoyuan 33305, Taiwan.
Yin-Cheng HuangDepartment of Medicine, Chang Gung University Taoyuan 33305, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite advancements in targeted therapy, glioblastoma remains a challenging condition with limited treatment options. While surgical techniques and external radiation therapy have improved, the median survival for glioblastoma stands at around 12-18 months, with a 5-year survival rate of only 6.8%. Epithelioid glioblastoma (eGBM) represents a rare subtype within the glioma spectrum. Utilizing patient-derived xenograft (PDX) models in mice offers a promising avenue for drug screening and translational research, particularly for this specific glioblastoma subtype. Establishing a stable PDX model for eGBM revealed consistent genetic abnormalities, including

Indexed as

BRAF V600ECDK4/6 inhibitorGlioblastoma multiformpatient derived xenograft

Identifiers

PMID39553226
PMCPMC11560820

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.